DE69109314D1 - Humaner monoklonaler Antikörper und diesen enthaltende Arzneimittelzusammensetzung zur Behandlung von Pseudomonasinfektionen. - Google Patents

Humaner monoklonaler Antikörper und diesen enthaltende Arzneimittelzusammensetzung zur Behandlung von Pseudomonasinfektionen.

Info

Publication number
DE69109314D1
DE69109314D1 DE69109314T DE69109314T DE69109314D1 DE 69109314 D1 DE69109314 D1 DE 69109314D1 DE 69109314 T DE69109314 T DE 69109314T DE 69109314 T DE69109314 T DE 69109314T DE 69109314 D1 DE69109314 D1 DE 69109314D1
Authority
DE
Germany
Prior art keywords
monoclonal antibody
human monoclonal
treatment
pharmaceutical composition
composition containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69109314T
Other languages
English (en)
Inventor
Tsuneo Kohzuki
Ikuko Uezumi
Kenji Irie
Hiroshi Ochi
Kazuhiko Horigome
Hiroshi Noguchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharmaceuticals Co Ltd
Original Assignee
Sumitomo Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharmaceuticals Co Ltd filed Critical Sumitomo Pharmaceuticals Co Ltd
Application granted granted Critical
Publication of DE69109314D1 publication Critical patent/DE69109314D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69109314T 1990-02-08 1991-02-08 Humaner monoklonaler Antikörper und diesen enthaltende Arzneimittelzusammensetzung zur Behandlung von Pseudomonasinfektionen. Expired - Lifetime DE69109314D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP3002090 1990-02-08

Publications (1)

Publication Number Publication Date
DE69109314D1 true DE69109314D1 (de) 1995-06-08

Family

ID=12292157

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69109314T Expired - Lifetime DE69109314D1 (de) 1990-02-08 1991-02-08 Humaner monoklonaler Antikörper und diesen enthaltende Arzneimittelzusammensetzung zur Behandlung von Pseudomonasinfektionen.

Country Status (5)

Country Link
EP (1) EP0441395B1 (de)
JP (1) JPH04211393A (de)
AT (1) ATE122100T1 (de)
CA (1) CA2035848A1 (de)
DE (1) DE69109314D1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004297218B2 (en) 2000-09-07 2012-03-01 Amgen, Inc. Human anti-Pseudomonas-aeruginosa antibodies derived from transgenic Xenomouse
CA2422204A1 (en) 2000-09-07 2002-03-14 John R. Schreiber Human antibodies against pseudomonas aeruginosa lps derived from transgenic mice
EP1479695B1 (de) * 2003-05-14 2010-02-17 Kenta Biotech AG Humaner monoklonaler Antikörper spezifisch für Lipopolysacchariden (LPS) des Serotyps IATS O6 von Pseudomonas aeruginosa
WO2013024905A1 (en) * 2011-08-16 2013-02-21 Meiji Seika Pharma Co., Ltd. Combination drug of antibody against lipopolysaccharide of pseudomonas aeruginosa and antibacterial agent
JP6494519B6 (ja) 2013-09-30 2019-07-31 第一三共株式会社 抗ｌｐｓ ｏ１１抗体
KR20180101341A (ko) * 2015-11-10 2018-09-12 비스테라, 인크. 리포폴리사카라이드에 특이적으로 결합하는 항체 분자-약물 접합체 및 그의 용도
EP3571223B1 (de) 2017-01-18 2024-09-18 Visterra, Inc. Antikörpermolekularzneimittelkonjugate und verwendungen davon
JP2023521319A (ja) 2020-04-03 2023-05-24 ビステラ， インコーポレイテッド 抗体分子－薬物コンジュゲートおよびその使用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0256713A3 (de) * 1986-08-06 1989-02-15 Merck & Co. Inc. Therapeutische, menschliche Antipseudomonas-Aeruginosa-Antikörper
GB2218703B (en) * 1988-05-10 1992-10-28 Sumitomo Chemical Co Human monoclonal antibody to p.aeruginosa: its production and use
JPH02299594A (ja) * 1989-01-30 1990-12-11 Sumitomo Chem Co Ltd ヒトモノクローナル抗体およびその製法

Also Published As

Publication number Publication date
JPH04211393A (ja) 1992-08-03
EP0441395A3 (en) 1991-10-16
EP0441395B1 (de) 1995-05-03
ATE122100T1 (de) 1995-05-15
EP0441395A2 (de) 1991-08-14
CA2035848A1 (en) 1991-08-09

Similar Documents

Publication Publication Date Title
DE69428130D1 (de) Verwendung von bcl-2 zur herstellung von arzneimitteln zur therapeutischen behandlung und verhinderung von krankheiten
DE3684190D1 (de) Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.
DE69533040D1 (de) Medikamente zur vorbeugung oder behandlung von vaskulären hämorrhagien
FI840748A (fi) Kinolonkarbonsyror, foerfarande foer deras framstaellning och dessa innehaollande antibakteriella aemnen.
ATE184792T1 (de) 2-bromomelatonin zur behandlung von schlafstörungen
ATE411026T1 (de) Mittel zur behandlung der alzheimer-krankheit
ATE101648T1 (de) Expression eines tumorspezifischen antigens eines rekombinanten virusvektors sowie dessen anwendung zur versorgenden oder heilenden behandlung des entsprechenden tumors.
PT76502A (en) Process for the preparation of n-glycosylated carboxamide derivatives with s stimulating effect of the body's inherent defences and their application for the preparation of pharmaceutical compositions having a stimulating effect of body's inherent defences
RU94020410A (ru) Способ лечения или профилактики рвоты у млекопитающих и человека с использованием некоторых хинуклидиновых, пиперидиновых, азанорборнановых, этилендиаминовых производных и родственных им соединений
RU92016463A (ru) Применение производных цистина для изготовления лекарственных препаратов с иммуномоделирующим действием, фармацевтические композиции на их основе
ATE85523T1 (de) Taurohyodeoxycholsaeure zur behandlung von gallenwegssteinen und gallenstoerungen.
ATE138567T1 (de) Zusammensetzung und verfahren zur behandlung von schmerzvollen entzündlichen oder allergischen erkrankungen
RU94008616A (ru) 2-тиозамещенные карбапенемы, промежуточные соединения для получения, способы получения, фармацевтическая композиция, способ лечения бактериальных инфекций
RU94045825A (ru) Применение материала, полученного из mycobacterium vaccae для производства терапевтического средства для лечения психических заболеваний, способ лечения психических заболеваний, продукт, содержащий антигенный и/или иммунорегуляторный материал, фармацевтическое средство
DE69109314D1 (de) Humaner monoklonaler Antikörper und diesen enthaltende Arzneimittelzusammensetzung zur Behandlung von Pseudomonasinfektionen.
ATE1443T1 (de) Mittel zur behandlung allergischer reaktionen.
ES481108A1 (es) Un metodo de preparacion de un extracto de inula.
ATE89728T1 (de) Verwendung von dihydroergotamin und seinen salzen zur lokalen behandlung trophischer stoerungen.
ATE148628T1 (de) 5-methylisoxazol-4-carbonsäure-anilide und 2- hydroxyethyliden-cyanoessigsäure-anilide zur behandlung von augenkrankheiten
DE69026511D1 (de) Verwendung von gibberellinen zur herstellung eines arzneimittels zur behandlung von prostatitis
DE69013431D1 (de) Anthocyanidine zur Behandlung von Augenkrankheiten.
OA09121A (fr) Nouveau sel de strontium, son procédé de préparation et les compositions pharmaceutiques le renfermant.
DE69116606D1 (de) Bacterin zur Behandlung von Necrophorum-Krankheiten und Verfahren zur Herstellung
DE3786173D1 (de) Menschlicher monoklonaler antikoerper und arzneimittel zur prophylaxe und behandlung von infektioesen krankheiten.
DE69010523D1 (de) Kit oder Zusammensetzung zur Vorbeugung oder Behandlung von HIV-1 Infektionen.

Legal Events

Date Code Title Description
8332 No legal effect for de